Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | POLARIS: encorafenib/binimetinib for advanced BRAFV600+ melanoma

Georgina Long • 28 Sep 2019
ESMO 2019
Melanoma Skin Cancer Binimetinib Encorafenib
POLARIS

Georgina Long, MD, PhD, FRACP, University of Sydney, Sydney, Australia, talks to us about the ongoing POLARIS trial (NCT03911869). The trial aims to investigate how encorafenib, a BRAF inhibitor, combined with the MEK inhibitor binimetinib interacts in the brain of patients with advanced melanoma and active brain metastasis. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Georgina Long

0:56
Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab
Georgina Long • 10 Sep 2022
0:36
Challenges associated with implementing ctDNA approaches in melanoma
Georgina Long • 10 Sep 2022
2:01
Pre-treatment ctDNA linked to increased risk of early recurrence in IO-treated melanoma
Georgina Long • 10 Sep 2022
1:20
NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma
Georgina Long • 10 Sep 2022

Related Videos

2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
1:20
Can ctDNA guide the treatment decision making process in melanoma?
Christoffer Gebhardt • 9 Apr 2024
1:18
Elucidating ICI resistance in melanoma with ctDNA and tumor profiling
Christoffer Gebhardt • 9 Apr 2024
1:48
Ultra-sensitive ctDNA monitoring predicts ICI response in melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals